Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.35 |
| ▸ | DRD3 | P35462 | 6/20 | 0.35 |
| ▸ | HTR1D | P28221 | 3/20 | 0.35 |
| ▸ | TLR4 | O00206 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 3/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17459541 | 1.00 | DRD2 (0.35) | DRD2DRD3HTR1DTLR4DRD4 | |
| SCHEMBL27111872 | 0.84 | DRD2 (0.31) | DRD2DRD3HTR1D | |
| SCHEMBL10014981 | 0.78 | DRD2 (0.40) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL19695843 | 0.76 | TLR4 (0.34) | TLR4 | |
| SCHEMBL17492906 | 0.76 | TLR4 (0.36) | TLR4 | |
| SCHEMBL17459535 | 0.76 | TLR4 (0.36) | TLR4 | |
| SCHEMBL15635112 | 0.74 | LMNA (0.34) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL3735441 | 0.73 | ALDH1A1 (0.38) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL7384939 | 0.66 | DRD2 (0.31) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL2754407 | 0.66 | DRD2 (0.31) | DRD2DRD3HTR1DDRD4DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | DRD2 775/4885DRD3 736/4885HTR1D 158/4885 |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | DRD2 775/4885DRD3 736/4885HTR1D 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.